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Ionizing radiation (IR) is used for patients diagnosed with unresectable non small cell lung cancer (NSCLC), however
radiotherapy remains largely palliative due to radioresistance. Cancer stem cells (CSCs), as well as epithelial-
mesenchymal transition (EMT), may contribute to drug and radiation resistance mechanisms in solid tumors. Here
we investigated the molecular phenotype of A549 and H460 NSCLC cells that survived treatment with IR (5Gy)
and are growing as floating tumor spheres and cells that are maintained in a monolayer after irradiation.
Non-irradiated and irradiated cells were collected after one week, seeded onto ultra low attachment plates and
propagated as tumor spheres. Bulk NSCLC cells which survived radiation and grew in spheres express cancer stem cell
surface and embryonic stem cell markers and are able to self-renew, and generate differentiated progeny. These cells
also have a mesenchymal phenotype. Particularly, the radiation survived sphere cells express significantly higher levels
of CSC markers (CD24 and CD44), nuclear β-catenin and EMT markers (Snail1, Vimentin, and N-cadherin) than non-
irradiated lung tumor sphere cells. Upregulated levels of Oct-4, Sox2 and beta-catenin were detected in H460 cells
maintained in a monolayer after irradiation, but not in radiation survived adherent A459 cells.
PDGFR-beta was upregulated in radiation survived sphere cells and in radiation survived adherent cells in both A549
and H460 cell lines. Combining IR treatment with axitinib or dasatinib, inhibitors with anti-PDFGR activity, potentiates
the efficacy of NSCLC radiotherapy in vitro.
Our findings suggest that radiation survived cells have a complex phenotype combining the properties of CSCs and
EMT. CD44, SNAIL and PDGFR-beta are dramatically upregulated in radiation survived cells and might be considered as
markers of radiotherapy response in NSCLC.
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Worldwide, lung cancer ranks highest in terms of both in-
cidence and mortality [1]. Despite decades of research,
systemic therapies fail to cure most lung cancers. Lung
cancers are comprised of two major histological types:
small-cell lung cancer (SCLC) and non-small-cell lung
cancer (NSCLC, i.e., adenocarcinoma, squamous cell car-
cinoma, and large cell carcinoma). NSCLC comprises 85%
of lung cancer cases and about 40% are unresectable [2].
Radiotherapy used for patients with unresectable NSCLC
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distribution, and reproduction in any medium[1,3] which is possibly due to tumor heterogeneity in terms
of cell of origin, pathology, etiology and molecular/genetic
pathogenesis [4]. The existence of cancer stem/progenitor
cells (CSCs) or tumor-initiating cells (TICs) reflects the
cellular heterogeneity within solid tumors [5-7]. These cells
are the undifferentiated cells with a high tumorigenic and
self-renewal capacity, which have been identified in various
human malignancies including breast, brain, prostate,
pancreatic, colon and lung cancer [8-13]. CSCs express
specific markers and stem cell genes and use common sig-
naling pathways including Wnt/β-catenin, Hedgehog and
Notch [5-7]. CSCs can be enriched as a subpopulation of
cells propagating as non-adherent spheres in medium
suitable for tumor stem cells [9]. Evidence suggests thatntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ence of CSCs which are resistant to chemo- and radio-
therapy [14-16].
The cell surface markers CD133, CD44, CD166, as
well as ABCG2 transporter and aldehyde dehydrogenase
1 family, member A1 (ALDHA1) protein, have also been
reported as human lung CSC markers [12,13,17-20].
Hoechst 33342 dye excluding cells, termed as side-
population (SP) cells, has been described as CSCs in a
variety of tumor types, including NSCLCs [21,22]. Oct-4
protein is also critically involved in the self renewal of un-
differentiated embryonic stem cells and is frequently used
as a marker for undifferentiated cells. We demonstrated
that lung cancer stem cells that survived treatment with
chemotherapeutic drugs express Oct-4 [13]. The role of
these important putative stem traits in lung CSCs were
confirmed in further studies [23-25]. The expression of
CSC-related markers, after chemo and radiation therapy,
significantly correlated with a poor prognosis in patients
with NSCLC [26], however direct confirmation of the role
of lung CSCs in NSCLC radioresistance is missing.
In cancers, epithelial-mesenchymal transition (EMT) is
also associated with resistance to chemotherapeutic
drugs and radiation [27,28]; epithelial tumor cells with
ongoing EMT develop CSC traits [29,30]. EMT is an
embryonic process leading to the loss of cell-cell contact,
repression of E-cadherin expression and increased cell
motility. EMT transition in epithelial cells leads to
switching from E- cadherin to N- cadherin [31].
As epithelial cancer cells undergo EMT, they gain
stemness, motility, invasiveness, drug resistance and an-
giogenic and metastatic ability. EMT is regulated by a
network of transcription factors including Snail, Slug,
Twist, Zeb, and others [29,30,32,33]. EMT can be acti-
vated by TGF-β and other oncogenic pathways (e.g., Src,
Ras, Notch) [32,34] and by tumor microenvironment
stresses (e.g., hypoxia) [35,36]. IR promotes EMT in
tumor cell lines via the activation of TFG β signaling
[37-40]. The alteration of the expression of the E -
cadherin/β-catenin complex is an independent poor
prognostic factor in human lung adenocarcinoma [41].
However, until now there have not been any studies that
have elucidated the CSC and EMT characteristics of
NSCLC cells that survived IR-treatment.
In the present study, we performed an extensive com-
parative phenotypic analysis of CSC and EMT marker
expression in bulk naïve adherent NSCLC cells, in ir-
radiation survived adherent cells, non-irradiated lung
tumor sphere cells and radiation–survived NSCLC cells
growing as tumor spheres using the High Content
Screening Approach (ThermoFisher, Cellomics INC).
Our findings demonstrate the role of CSC and EMT
in radiation survived tumor sphere cells and may lead to
the identification of the new therapeutic targets.Materials and methods
Cell lines
The human A549 and H460 NSCLC cell lines were pur-
chased from the American Type Culture Collection (ATCC).
Cells were grown in culture media, as recommended by the
ATCC, that was supplemented with 10% FBS (Millipore
Inc., Billerica, MA).
Reagents
Hoechst 33342 was purchased from Sigma-Aldrich (Sigma-
Aldrich, St. Louis, MO). Fluorochrome-conjugated antibody
against human CD44 was from Beckman Coulter (Fullerton,
CA). Antibodies against PDGFR-a; PDGFR-beta, CD166
and Sox-2 were from R&D Systems INC (Minneapolis,
MN). Antibodies against CD24, Snail1, Twist1, Slug,
N-cadherin, Vimentin, Fibronectin, ALDH1A1 and pancy-
tokeratin were from Abcam Inc. (Abcam, Cambridge, MA).
Oct-4 and E-Cadherin antibodies were purchased from Cell
Signaling Technology Inc., (Cell Signaling, Danvers, MA).
CD133 antibody was obtained from Miltenyi Biotec
(Germany). Alexa Fluor®-488 conjugated mouse antibody
against human ß-catenin were purchased from BD Biosci-
ences Inc. (San Diego, CA). Secondary antibody conjugated
with Alexa®-488, -546, and-680 was from Molecular Probes
(Invitrogen, Carlsbad, CA).
The Tyrosine kinase inhibitors, Axitinib and Dasatinib,
were purchased from LC Laboratories (Woburn, MA).
Irradiation
NSCLC cells were irradiated, as cell suspension or as
monolayer, using the Shepherd Mark 1 68 Irradiator,
(137Cs Irradiator) (JL Shepherd, San Fernando, CA,
USA) dose rate of 70.6 rad/min at room temperature.
In vitro clonogenic assays
Exponentially growing H460 and A549 cells were
harvested by exposure to trypsin and cell suspensions
were irradiated using a 137Cs gamma-ray source with
doses ranging from 0 to 10 Gy and plated in 6 well
plates, 500 cells per well. Cultures were incubated at 37°C
in 5% CO2. The next day, axitinib or dasatinib was added
to the cultures at a final concentration of 1 μM. The
culture media with inhibitors was changed every day.
Seven days later the cells were fixed and stained with
crystal violet; colonies ≥50 cells were counted and the
size of the colonies were measured (Gel Count colony
counter, Oxford Optronix, Oxford, UK). Data was ana-
lyzed with linear quadratic and single-hit multi-target
models [42].
Culture of irradiated cells
Cells were seeded at a density of 2 × 105 cells/well, in
12-well plates containing RPMI, supplemented with 10%
FBS. After overnight incubation, cells were irradiated
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5% CO2. Medium replacement was done every third day
with fresh medium.
To obtain adherent radiation survived cells, cells were
kept in the plates for two weeks. To analyze EMT and
CSC markers in adherent radiation survived cells, cells
were harvested, counted and seeded into 96 well plates
containing RPMI, supplemented with 10% FBS. The next
day, the cells were fixed, immunofluorescently stained and
analyzed as described below. To analyze cell motility, ad-
herent radiation survived cells were collected and seeded
into 6 well plates containing RPMI, supplemented with
10% FBS and a wound healing assay was applied.
To generate radiation survived tumor sphere cells,
seven days after IR treatment the cells were harvested,
filtered, counted and used for lung tumor sphere assays.
Culture of lung tumor spheres
Suspension growth was assessed in methyl cellulose-based
(0.8% MC) medium as described [9,11]. Briefly, NSCLC
cells and IR-survived cells were resuspended in 0.8% MC-
based serum free medium (Stem Cell Technologies, Van-
couver, Canada) and supplemented with 20 ng/mL EGF
(BD Biosciences), bFGF and 4 μg/mL insulin (Sigma) and
plated at 500-10000cells/mL in ultra low attachment 24–96
well plates (Corning, Corning, NY) for 12 days. The
medium was replaced or supplemented with fresh growth
factors (EGF, bFGF (20 ng/mL) and insulin (4 μg/mL))
twice a week. The tumor sphere growth was analyzed
under a phase-contrast microscope with an ×10 objective
and counted from multiple wells.
Self renewal
In order to assess the self renewing potential of the cells,
spheres of the first generation were collected by gentle
centrifugation, dissociated into single cell suspensions,
filtered through a 30 μm filter and cultured in ultra low
attachment plates in stem cell selective medium as de-
scribed above. The tumor sphere growth was analyzed
under a phase-contrast microscope with a 10× objective
and counted from multiple wells. To generate spheres of
the 3rd, 4th and 5th generations, the 2nd, 3rd and 4th
generation tumor spheres were collected; the single cell
suspensions were prepared and were replated. The
tumor spheres were counted after 12 days.
Differentiation
Cells dissociated from spheres (third generation) were
plated at 1 × 104 cells/mL on 96-well plates that were
precoated with Collagen IV (BD Biosciences), in culture
media supplemented with 10% FBS and transferred into
new plates when cultures reached confluence. To test
the self renewing potential of differentiated cells, they
were transferred into semisolid serum-free mediasupplemented with EGF, FGF and insulin and their abil-
ity to form tumor spheres was evaluated, as described
above. To perform a phenotypic characterization of the
cells, from spheres and after differentiation, the cells
were seeded in 96 well plates (5 × 103 cells/well) and
stained with various antibodies as described above.
Monolayer wound healing assay
Cells were seeded into the six-well plates at high density
and were cultured for 2 days to produce a monolayer.
Cells were plated, scratched and monitored in the media
supplemented with 10% FBS. Confluent cell monolayers
were then scratched using a plastic 10 μL-pipette tip as
described [43]. Wounded monolayers were then washed
four times with medium to remove cell debris and incu-
bated in a culture medium supplemented with 10% FBS
for 24 h. Images were captured in 0, 2, 4, 6 and 24 h using
a ZEISS (light) microscope Axiovert 40C (Hamamatsu).
Cell staining procedure for cellomics arrayscan
automated imaging
Cells were fluorescently stained as previously described
[13,44]. Briefly, cells grown in 96-well plates were fixed,
washed with FACS buffer, incubated with antibodies
against CD24, CD34, CD44, CD117, CD166, conjugated
with FITC, PE or PC5 for 1 h; fixed in 2% PFA for
20 min, washed in PBS, and stained with Hoechst 33342.
To test CD133, PDGFRα, PDGFRβ and CXCR4 expres-
sion, cells were incubated with respective primary anti-
bodies and then with secondary antibodies that were
conjugated with Alexa 488, 546, or 680 fluorochromes
(Molecular Probes/Invitrogen) for 1 h. Cell nuclei were
then stained with Hoechst 33342 at 2 μg/ml for 20 mi-
nutes to identify individual cells and to optimize focus-
ing. To detect intracellular proteins, cells were fixed and
permeabilazed and then stained for ß-catenin, Sox-2,
Snail1, Twist1 and cytokeratins using primary and sec-
ondary antibodies conjugated with Alexa®- 488, 546 or
680 dyes (Molecular Probes/Invitrogen) as described
above. All incubation and fixation procedures were
performed at room temperature.
Cellomics array scan automated imaging
The Cellomics ArrayScan HCS Reader (Cellomics/
ThermoFisher, Pittsburgh, PA) was utilized to collect in-
formation on the distribution of fluorescently labeled
components in stained cells. The ArrayScan HCS system
scans multiple fields in individual wells, acquiring and
analyzing each of the cell images according to defined al-
gorithms. The scanner is equipped with emission and ex-
citation filters (XF93, Omega Optical, Brattleboro, VT,
USA) for selectively imaging fluorescent signals. Data was
captured, extracted and analyzed with ArrayScan II Data
Acquisition and Data Viewer version 3.0 (Cellomics),
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Canada) and MS Excel 2002 (Microsoft, Redmond, WA).
Statistical analysis
Experiments were performed at least three times. Com-
parisons between values were performed using a two-
tailed Student’s t-test. For the comparison of multiple
groups, a one- or two-way ANOVA test was applied. For
all statistical analyses, the level of significance was set at
a probability of 0.05.
Results
Generation of NSCLC cells survived ionizing radiation and
propagated as tumor spheres
A549 and H460 bulk NSCLC cells were treated with
clinically relevant doses of IR (5.0 Gy) and cultured for
one week. The majority of cells died by the fifth day and
enlarged cells were seen with flattened, senescent-like
morphology. Radiation survived cells started clonogenic
growth (Figure 1A, top images).Figure 1 The radiation survived NSCLC cells express cancer stem cell
adherent conditions for a week. Cells were collected and plated as single
tumor spheres. To obtain adherent radiation survived cells, cells were kept
were tested in non-irradiated cells, adherent cells that survived IR treatmen
(A) Morphology of adherent cells that survived IR treatment and spheres d
populations are enriched in the tumor-sphere forming cells. Non-irradiated
the stem cell selective conditions. 10 days later the tumor spheres, from th
spheres, from the first generation, were used to develop the tumor sphere
were used to develop the third generation spheres used for further study.
plates were fixed, incubated with the respective antibody and stained with
Reader (40× objective) and analyzed using the Target Activation BioApplica
radiation survived sphere cells stained for CD44 and CD166 are shown. (D-
CD166 (F) in the non-irradiated cells (grey), IR- survived adherent cells (gre
(blue) are presented. The fluorescence intensities of respective IgG controls
estimated for 3000 cells.On the seventh day after irradiation, the cells were col-
lected, filtered and plated as single cell suspensions in
stem-cell selective conditions: ultra-low attachment plates,
serum free media supplemented with growth factors to
form floating tumor spheres. As shown in Figure 1A,
IR-survived A549 and H460 cells proliferated and gener-
ated floating clones or tumor spheres.
Growth as tumor spheres is considered to be a surrogate
marker for stemness and self renewal ability in epithelial
cancers [9]. The ability to form tumor spheres in low at-
tachment growth conditions is a good index of the tumor-
forming potential of stem cells. We have analyzed the
tumor sphere formation in the radiation survived adherent
clones as well as the parental NSCLC cells. As shown in
Figure 1B, the numbers of first generation tumor spheres
which developed from adherent radiation survived cells,
was significantly higher than the number of spheres which
developed from non-irradiated parental NSCLC cells.
Next, we developed second and third generation
tumor spheres using our published approach [13]. Themarkers. A549 and H460 cells were irradiated (5Gy) and cultured in
cell suspensions, in stem-cell selective conditions, to form floating
in the plates for two weeks after IR-treatment. Expressions of markers
t, non-irradiated sphere cells, and sphere cells that survived irradiation.
eveloped from IR-treated cells are shown. (B) Radiation survived cell
cells and radiation survived cells were harvested, and transferred into
e first generation, were counted under the microscope. The tumor
s for the second generation. The second generations of tumor spheres
(C-F) Analysis of CD44, CD24 and CD166 expression. Cells in 96-well
Hoechst33342. Cell images were acquired using the ArrayScan HCS
tion Software Module. (C) The representative images of the A549
F) The total average fluorescence intensities of CD24 (D), CD44 (E) and
en), non-irradiated sphere cells (red) and in the IR-survived sphere cells
were subtracted. Each point presents average intensities (pixels)
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further study.
In addition, A549 and H460 cells that survived IR
treatment (5.0 Gy), in adherent monolayer cultures, were
used in the comparative study.
Analysis of lung cancer stem cell traits
To determine whether the radiation survived cells have
other intrinsic properties of stem cells, immunofluores-
cent staining and HCA and HCS analyses from
Cellomics, ThermoFisher, for expression of CSC and em-
bryonic transcription factors were used. The compara-
tive analyses of CSC markers in non-irradiated NSCLC
cells, radiation survived adherent cells, non-irradiated
lung tumor sphere cells, and radiation survived cells
growing in tumor spheres was performed (Figure 1C-F).
Non-irradiated lung sphere cells, as well as radiation
survived sphere cells, showed significant upregulation of
CD44 and CD166, as compared with parental NSCLC
cells in both cell lines, which corresponds to the previ-
ously identified phenotypic markers of human lung
CSCs. CD44 expression was significantly higher in the
radiation survived sphere cells than in non-irradiatedFigure 2 The radiation survived NSCLC cells show upregulation of be
NSCLC cells, radiation survived adherent cells, non-irradiated sphere cells an
collagen precoated 96-well plates. 8 hours later the cells were fixed, perme
Sox-2. The cell nuclei were stained with Hoechst33342. Cell images were a
analyzed using the Compartment Analysis BioApplication Software Module
radiation survived adherent cells, non-irradiated sphere cells and radiation
total average fluorescence intensities of nuclear beta-catenin (B), Oct-4 (C)
survived adherent cells (green), in the non-irradiated sphere cells (red) and
Fluorescence intensities of respective IgG controls were subtracted. Each psphere cells in both cell lines, whereas CD166 was sig-
nificantly upregulated in sphere cells generated from IR-
treated A549 cells. CD44 and CD166 levels were also
higher in radiation survived adherent H460 cells, than in
non-irradiated bulk H460 cells.
Interestingly, CD24 upregulation was observed only in
radiation survived sphere cells and was not elevated in
non-irradiated lung spheres cells or radiation survived
adherent cells in comparison to bulk NSCLC cells in
both cell lines (Figure 1D).
We next analyzed the expression of transcription fac-
tors correlating with stemness (beta- catenin, Oct-4, and
Sox-2) in non-irradiated NSCLC cells, radiation survived
adherent cells, non-irradiated sphere cells and in the ra-
diation survived sphere cells (Figure 2). As shown for
beta-catenin (Figure 2A), these transcription factors are
mainly located in the nuclei of the cells. Beta-catenin
upregulation has been detected in the radiation survived
sphere cells in both cell lines (Figure 2B). A substantial
increase in Oct-4 has been found only in A549 radiation
survived sphere cells, whereas upregulation of the Sox-2
transcription factor has been observed only in H460 ra-
diation survived sphere cells (Figure 2C-D). However, inta-catenin, Oct-4 and Sox-2 transcription factors. Non-irradiated
d radiation survived sphere cells were collected and seeded into
abelized and immunofluorescently stained for beta-catenin, Oct-4 and
cquired using the Cellomics ArrayScan HCS Reader (40× objective) and
. (A) The representative images of parental non-irradiated H460 cells,
survived sphere cells stained for beta-catenin are shown. (B-D) The
and Sox-2 (D) in the non-irradiated NSCLC cells (grey), in the radiation
in the radiation survived sphere cells (blue) are presented.
oint presents average intensities (pixels) estimated for 3000 cells.
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associated transcription factors (e.g. β-catenin and Oct-
4; β-catenin and Sox-2) in radiation survived sphere cells
suggests that these cells might have more pluripotent and
aggressive phenotypes than non-irradiated lung tumor
sphere cells. Radiation survived adherent H460 cells dis-
play upregulation of stemness-associated transcription fac-
tors, Oct-4, Sox2 and beta –catenin, whereas radiation
survived adherent A549 cells have shown the same low
level of these transcription factors as adherent non-
irradiated bulk A549 cells.
Radiation survived sphere cells could be propagated
for at least 10 passages after mechanical disaggregation
of the spheres into a single cell suspension and replating
into low-adherence conditions in serum-free media
supplemented with growth factors. Limiting dilution ex-
periments showed that the percentage of clonogenic
cells, in spheres generated from IR –escapees, was 22%
and 27% in cells derived from H460 and A549 cell lines,
respectively, and did not change in subsequent passages.
If radiation- survived sphere cells were disaggregated
and plated in collagen precoated plates with culture
media supplemented 10% FBS, they adhered and started
proliferating. After four weeks of culture under adherent
conditions in culture media supplemented with FBS, the
cells differentiated and acquired an epithelial morph-
ology with decreased expression of CD44, CD24 and
CD166 (data not shown).
Analysis of epithelial to mesenchymal transition (EMT)
markers
We studied a number of markers associated with EMT
using immunofluorescent staining and the Compartment
Analysis BioApplication Software Module from Cellomics
which allows us to quantify fluorescence signals in nuclear
and cytoplasm compartments of the cells.
Non-irradiated sphere cells, as well as radiation survived
sphere cells, showed an upregulation of EMT-related tran-
scription factor Snail1 as compared to adherent parental
and IR treated H460 and A549 cells. However, the level
of Snail1 expression was significantly higher in radiation
survived sphere cells than in non-irradiated sphere cells
(Figure 3A). Snail1 was detected in the nuclear and in
the cytoplasm compartments of the cells (Figure 3B,C).
In contrast, the up-regulation of the EMT-related tran-
scription factor Twist was observed only in the radiation
survived sphere cells originated from A549 cell line and
Twist was mainly located in the cell nucleus (Figure 3D,E).
Radiation survived sphere cells and non-irradiated sphere
cells that originated from H460 cell line expressed the
same low levels of Twist as the parental H460 cells
(Figure 3D,F).
To further confirm the EMT phenotype of radiation
survived sphere cells, we analyzed the expression offibronectin, vimentin, N-cadherin, and E-cadherin
Figure 4). As shown in Figure 4, non-irradiated sphere
cells and radiation survived sphere cells demonstrated
strong upregulation of vimentin and N-cadherin when
compared with the adherent bulk and IR treated cell
populations, however, this EMT marker expression was
significantly higher in radiation survived sphere cells
than in non-irradiated sphere cells in both cell lines.
Fibronectin was elevated only in sphere cells and radi-
ation survived sphere cells of the A459 cell line but
not of the H460 cell line. In contrast, repression of
E-cadherin expression was observed in radiation sur-
vived sphere cells when compared with bulk NSCLC
cells and non-irradiated sphere cells (Figure 4) in A459
and also H460 cell lines.
Analysis of cell migration
Next, we tested whether EMT marker expression, in ra-
diation survived sphere cells, was associated with in-
creased cell motility. Migratory rates of non-irradiated
NSCLC cells, radiation survived adherent cells, non-
irradiated lung tumor sphere cells and radiation–sur-
vived cells growing in tumor spheres were monitored in
an in vitro wound healing assay. As shown in Figure 5,
sphere cells, non-irradiated and radiation survived, were
able to reestablish a monolayer significantly faster than
non-irradiated and radiation survived adherent H460
and A549 cells. For sphere cells, non-irradiated and radi-
ation survived, wounds closure was complete at 24 h
after the scratching, whereas adherent NSCLC cells did
not complete wound healing at 24 hours. This data indi-
cates that tumor spheres cells have a higher motility
than adherent NSCLC cells.
Analysis of CXCR4 and PDGFR receptors expression
Upregulation of CXCR4 is functionally crucial for the
maintenance of stemness in drug-resistant NSCLC cells
[13,45]. Platelet-derived growth factor receptor (PDGFR)
signaling plays a crucial role in specifying the mesen-
chymal stem cell (MSC) commitment to mesenchy-
mal lineages [46]. Therefore, we investigated CXCR4,
PDGFRα and PDGFRβ expression in non-irradiated bulk
NSCLC cells, radiation survived adherent cells, non-
irradiated sphere cells and radiation survived sphere
cells (Figure 6). An increase of expression of CXCR4, in
non-irradiated sphere cells and radiation survived sphere
cells, was observed (Figure 6A,B). PDGFRα was not de-
tectable in any of the four cell populations investigated
(data not shown). PDGFR beta was also undetectable in
non-irradiated H460 and A549 cells and non-irradiated
lung tumor sphere cells. In contrast, radiation survived
cells, adherent cells and sphere cells, in both cell lines
showed a significant increase of PDGFR beta expression
(Figure 6C).
Figure 3 Upregulation of EMT-associated transcription factors Snail1 and Twist in radiation survived sphere cells. Non-irradiated NSCLC
cells, radiation survived adherent cells, non-irradiated sphere cells and radiation survived sphere cells were collected and seeded into collagen
precoated 96-well plates. 8 hours later, the cells were fixed, permeabilazed and immunofluorescently stained for Snail1 and Twist. The cell nuclei
were stained with Hoechst33342. Cell images were acquired using the Cellomics ArrayScan HCS Reader (40× objective) and analyzed using the
Compartment Analysis BioApplication Software Module. Fluorescence intensities of respective IgG controls were subtracted. Each point presents
average intensities (pixels) estimated for 3000 cells. (A-C) Analysis of Snail1 expression. The total average fluorescence intensities of Snail1 (A) in
the non-irradiated NSCLC cells (grey), in the radiation survived adherent cells (green), in the non-irradiated sphere cells (red) and in the radiation
survived sphere cells (blue) are presented. (B,C) Snail1 distributions, in the nuclei and cytoplasm compartments of the same cell populations, are
shown. (D-F) Analysis of Twist expression. The total average fluorescence intensities of Twist (D) in the non-irradiated NSCLC cells (grey), in the
radiation survived adherent cells (green), in the non-irradiated sphere cells (red) and in the radiation survived sphere cells (blue) are presented.
(E,F) Twist distributions, in the nuclei and cytoplasm compartments of the same cell populations, are shown.
Figure 4 The radiation survived lung tumor sphere cells show upregulation of EMT markers. Non-irradiated A549 and H460 cells, radiation
survived adherent cells, non-irradiated sphere cells and radiation survived sphere cells were collected and seeded into collagen precoated 96-well
plates. Eight hours later, cells were stained for fibronectin, vimentin, N-cadherin and E-cadherin. The cell nuclei were stained with Hoechst33342.
Cell images were acquired using the Cellomics ArrayScan HCS Reader (40X objective) and analyzed using the Target Activation BioApplication
Software Module. The total average fluorescence intensities of fibronectin (A), E-cadherin (B), vimentin (C), and N-cadherin (D), in the non-irradiated
bulk NSCLC cells (grey), in the radiation survived adherent cells (green), in the non-irradiated sphere cells (red) and in the radiation survived sphere
cells (blue) are presented. Fluorescence intensities of the respective IgG controls were subtracted. Each point presents average intensities (pixels)
estimated for 3000 cells.
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Figure 5 Wound healing assay demonstrates high migratory potential of the radiation survived sphere cells. Non-irradiated NSCLC cells,
radiation survived adherent cells, non-irradiated sphere cells and radiation survived sphere cells were collected and grown to monolayers in 6-well
plates. Then cells were scratched and incubated for 0–24 hours. (A,B) The migratory rates of the bulk NSCLC cells (grey), of the radiation survived
adherent cells (green), of the non-irradiated sphere cells (red) and of the radiation survived sphere cells (blue) in a wounding assay, were determined
by measuring wound width as a function of time. Data are expressed as the mean ± SD of three experiments.
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To test whether PDGFR beta inhibition will potentiate
the effect of IR treatment on NSCLC cells we used
axitinib and dasatinib, the tyrosine kinase inhibitors with
anti-PDGFR beta activity, in clonogenic survival assay.Figure 6 Radiation- survived sphere cells display upregulation of CXC
adherent cells, non-irradiated sphere cells from the third generation, and radia
plates for 8 hours. The cells were fixed and immunofluorescently stained for C
Cell images were acquired using the Cellomics ArrayScan HCS Reader (40× ob
Module. (A) Fluorescence intensity of CXCR4 in non-irradiated A549 cells (bro
cells (red) plotted against the object area. Each spot represents a single cell. C
(B,C) The total average fluorescence intensities of CXCR4 (B) and PDGFR-beta
adherent cells (green), in the non-irradiated sphere cells (red) and in the radia
respective IgG controls were subtracted. Each point presents average intensitiThe results of the clonogenic survival assay presented in
Figure 7 and Table 1 demonstrate that combining IR treat-
ment with PDGFR inhibition increases the antitumor ef-
fect of ionizing radiation. A significant reduction of the
proliferating fraction of the NSCLC cells was determinedR4 and PDGFR-beta receptors. Bulk NSCLC cells, radiation survived
tion survived sphere cells were seeded into collagen precoated 96-well
XCR4 and PDGFR-beta. The cell nuclei were stained with Hoechst33342.
jective) and analyzed using the Target Activation BioApplication Software
wn), non-irradiated sphere cells (green), and radiation survived sphere
ells to the right of the black line are positive (above IgG control staining).
(C), in non-irradiated bulk NSCLC cells (grey), in the radiation survived
tion survived sphere cells (blue) are shown. Fluorescence intensities of
es (pixels) estimated for 3000 cells.
Figure 7 Clonogenic analysis of cells treated with PDGFR inhibitors and IR. Cells were suspended, counted, irradiated (0–10 Gy) and plated.
The next day, axitinib or dasatinib were added or not into the culture media. Then culture media with inhibitors was changed every day. Cells
were fixed and clonogenic survival was estimated on the seventh day after IR treatment. (A) Representative images of A549 cell clones generated
from IR (3Gy) treated or non-treated cells and growing in presence/absence of axitinib or dasatinib. (B) Comparison of clone sizes grown from
A549 cells irradiated (3 Gy) or non-irradiated and growing in presence/absence of axitinib or dasatinib. (C,D) Radiation survival curves show
radiation sensitivity of A549 (C) and H460 (D) cells growing without inhibitors (red line), growing in the presence of axitinib (1 μM, blue line)
or dasatinib (1 μM, green line). Average data of 5 experiments are presented.
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However, the treatment of irradiated cells with dasatinib
resulted in the biggest reduction of clonogenic survival in
the both cell lines.
Discussion
In the present study, we demonstrate that NSCLC cells
that survived ionizing radiation treatment have a complex
phenotype which includes all of the properties of CSCs
and markers of EMT. Evidence has recently been accumu-
lating to support the hypothesis that tumors contain a
small population of CSCs, also known as tumor initiating
cells, which exhibit stem-like cell properties including self-
renewal, tumor sphere formation, differentiation and
tumor formation in a xenotransplant model [9,47].Table 1 Comparison of radiosensitivity of NSCLC cells treated
Cell line A549
Treatment IR IR + Dasatinib IR + Axitin
D0 1.058 ± 0.07 0.920 ± 0.05 1.015 ± 0
p (vs IR) - 0.006 0.149
ñ 2.773 ± 0.43 1.464 ± 0.30 1.892 ± 0
p (vs IR) - <0.0001 0.027
Results were calculated with linear quadratic and single hit multi-target models and
cells to 37% and ñ (extrapolation number derived by extension of the linear propor
log/linear plot).CD166/ALCAM is a 100–105 kD type I transmembrane
glycoprotein member of the immunoglobulin superfamily
of proteins [48], which has also recently been reported as
a CSC marker in colorectal and lung cancers [20,49]. Our
finding that CD166/ALCAM expression is increased in
non-irradiated A549 and H460 lung sphere cells and even
more dramatically upregulated in radiation survived
sphere cells of the A549 cell line suggests that CD166/
ALCAM might serve as a marker for the detection of
CSCs and radioresistant counterparts within NSCLC tu-
mors and bears the potential to predict the outcome of
radiotherapy by assessment of CSC density. We demon-
strate here that the elevated level of CXCR4 expression
could also be considered as a marker for non-irradiated
human lung sphere cells and also for radiation survivedwith RTK inhibitors
H460
ib IR IR + Dasatinib IR cp Axitinib
.03 1.077 ± 0.11 0.914 ± 0.11 1.047 ± 0.12
- 0.009 0.406
.22 4.454 ± 1.72 2.206 ± 1.13 2.630 ± 0.61
- 0.011 0.029
presented as D0 –Gy, the dose required to reduce the fraction of survived
tion of the radiation survival curve to the ordinate of the graph using a
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ceptor of stromal derived factor (SDF/ CXCL12), has been
reported as functionally crucial for the maintenance of
stemness in drug-resistant NSCLC cells [13,45].
CD44, a receptor for hyaluronic acid and a well known
stem cell marker in many epithelial cancers, is a cell-sur-
face glycoprotein involved in cell–cell interactions, cell
adhesion and migration [50,51]. CD44 can also interact
with other ligands including growth factor receptors
such as EGFR2 and PDGFR, osteopontin, collagens
and matrix metalloproteinases (MMPs) which are in-
volved in tumor progression and metastasis [52]. CD44
gene transcription is, at least in part, activated by beta-
catenin and Wnt signaling [53]. A recent study discov-
ered CD44 as a marker which significantly correlates
with response to radiotherapy in early stage larynx can-
cer patients, both at the mRNA and protein levels [54].
As both CD44 and nuclear beta- catenin are dramatic-
ally upregulated in radiation survived lung cells, we
hypothesize that CD44/beta-catenin expression might
serve as another predictive marker for recurrence after
NSCLC radiation therapy.
Oct-4 and Sox-2 are stem cell transcription factors [55].
Our finding that Oct-4 and Sox-2 are highly upregulated
in radiation survived sphere cells from the A549 cell line
and highly upregulated in radiation surviving adherent
H460 cells, in comparison to respective naïve lung adher-
ent NSCLC cells and sphere cells, is suggesting that radi-
ation treatment may select for aggressive tumorigenic
phenotype, and that this selection is cell line specific. Re-
cently, it was reported that ionizing radiation induced a
breast CSC phenotype in non-stem cell populations. This
transition was Notch-dependent and coincided with up-
regulation of Oct-4 [56].
EMT can be a player in cancer initiation, promoting
the clonal expansion of premalignant epithelial cells
[57]. Cancer cells undergoing EMT acquire the capacity
to migrate, invade the stroma and metastasize. During
metastasis, the EMT program enables these cancer cells
to propagate from a primary tumor and also supports
progression from micro- to macro-metastases [58,59].
We found that radiation survived sphere cells also show
upregulation of the signal transducer CD24, whereas
non-irradiated sphere cells display very low levels of
CD24. It is conceivable that CD24 upregulation is dis-
criminating the EMT phenotype in radiation survived
cells. In many tumor types, CD24 expression is associ-
ated with metastasis [60]. Recently, CD24+ ovarian can-
cer cells exhibiting EMT phenotype were reported [61].
EMT is an embryonic process leading to loss of cell-cell
contact, repression of E-cadherin expression and in-
creased cell motility. EMT transition in epithelial cells
leads to switching from E-cadherin to N-cadherin [31].
In cancers, EMT is also associated with resistance tochemotherapeutic drugs and radiation [27,28], and epi-
thelial tumor cells undergoing EMT may develop CSC
traits [29,30].
Our observation is that lung sphere cells, non-irradiated
and radiation survived cells, have higher motility in com-
parison to adherent non-irradiated and radiation survived
NSCLC cells, as detected by a wound healing assay in vitro,
as well as upregulation of EMTassociated markers in radi-
ation survived lung sphere cells, which clearly indicates
that radiation survived sphere cells have a very complex
phenotype combining both human lung CSC and EMT
characteristics.
Radiation survived sphere cells demonstrated down-
regulation of E-cadherin and upregulation of N-cadherin,
fibronectin and vimentin in comparison with parental
A549 and H460 cells thus confirming EMT activation in
the cells. The E-cadherin promoter is repressed directly or
indirectly by specific developmental transcription factors
such as Twist1 and Snail1, disrupts the polarity of epithe-
lial cells and maintains a mesenchymal phenotype [59,62].
Interestingly, N-cadherin, vimentin and Snail1 upregu-
lation were also observed in the non-irradiated sphere
cells, however, the levels of these proteins were signifi-
cantly higher in the radiation survived sphere cells. Snail1
is a zinc-finger transcription factor belonging to the Snail
super family and it is characterized by a strongly conserved
carboxy-terminal region containing four to six C2H2-zinc
fingers. Snail1 acts as a transcriptional repressor, when the
fingers bind to E-box motifs (5′-CANNTG-3′) in target
promoters, including the E-cadherin gene (CDH1) pro-
moter. Snail is a critical transcriptional repressor of
E-cadherin and its expression induces EMT [29,63]. Snail
upregulation is associated with radioresistance and chemo-
resistance in epithelial tumors [64,65]. Twist is a basic
helix-loop-helix (bHLH) transcription factor, which plays
critical roles throughout development, including influen-
cing mesoderm formation, neurogenesis, myogenesis and
neural crest cell migration and differentiation [66]. A num-
ber of reports have implicated Twist1 in oncogenesis
through its ability to inhibit DNA damage-induced apop-
tosis and promote metastasis through the induction of
EMT [67]. Increased Twist1 expression is correlated with
the increased risk of metastasis and poor prognosis in a
number of solid tumor types including breast, prostate,
ovarian and lung [68,69].
The radiation survived sphere cells originated from
both A549 and H460 cell lines expressed a high level of
Snail1, whereas Twist upregulation was observed only in
radiation survived cells that originated from the A549
cell line. This finding suggests differential levels of EMT
activation in radiation survived cells and that the radi-
ation survived sphere cells originating from the A549
cell line have a more advanced EMT phenotype. This
suggestion is in concordance with the reports that Snail1
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that lead to the initiation of the invasive process,
whereas Twist1 has a critical role in the development of
distant metastases by prompting breast cancer cells to
enter the bloodstream [63,70]. A combination of EMT
and stem cell–like phenotypes is an important predictor
of aggressive biologic behavior and has an independent
prognostic value in predicting the outcome of primary
gastric cancer [71]. However, additional studies are ne-
cessary to clarify the impact of these cell subpopulations
in NSCLC radiation resistance.
Platelet derived growth factor (PDGF) and its recep-
tors play an important role in tumor cell migration and
vasculature formation, and these molecules are also well
known drivers of mesenchymal cell proliferation [72,73].
We revealed that PDGFR- beta was undetectable in non
treated parental cells and non-irradiated lung sphere
cells; however it was highly expressed in radiation sur-
vived sphere cells and adherent radiation survived cells.
PDFGR- beta is a receptor tyrosine kinase (RTK) whose
downstream signaling is effectively abrogated by second
generation RTK inhibitors, such as Axitinib (AG-
013736) [74] and dasatinib [75,76]. Using a classical
clonogenic assay for testing the effect of ionizing radi-
ation, axitinib, dasatinib and the combination of IR with
axitinib or dasatinib treatment, we observed that RDGFR
signaling may be important for NSCLC radiation resist-
ance as the combination of IR with dasatinib or axitinib
treatment significantly increases the efficacy of IR treat-
ment in NSCLC cells. However, combining IR with
dasatinib exerts a more profound effect than the com-
bination of IR with axitinib.
In conclusion, the present study demonstrates that
NSCLC cells that survived IR treatment and propagated
as tumor spheres have a complex phenotype which in-
cludes f the properties of CSCs. They have a significant
upregulation of CD166, CXCR4, CD44, nuclear beta-
catenin, Oct-4, and/or Sox-2 expression and they acquire
motility. Radiation survived cells also show an EMT
phenotype, including a reduction of E-cadherin and an
upregulation of N-cadherin and vimentin. These cells also
demonstrate an upregulation of Snail1, a major transcrip-
tion factor involved in EMTactivation and promotion.
PDGFR-beta signaling, which is specifically upregulated
in radiation survived sphere cells and IR-treated adherent
cells, could be considered as prognostic markers for
NSCLC radiation therapy and they may also serve as the
targets for improving the efficacy of NSCLC therapy.
Further in vivo studies of radiation survived cells may
provide key information on relevant pathways to be
targeted to increase the radiation response in NSCLC.Competing interests
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